Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/8528
Title: Infliximab therapy for familial Mediterranean fever-related amyloidosis: Case series with long term follow-up
Authors: Özçakar, Z.B.
Yüksel, Selçuk
Ekim, M.
Yalçinkaya, F.
Keywords: Amyloidosis
Familial Mediterranean fever
Infliximab
Pediatric
adalimumab
albumin
amyloid A protein
colchicine
creatinine
digoxin
etanercept
infliximab
isoniazid
phosphorus
potassium
recombinant interleukin 1 receptor blocking agent
abdominal pain
adolescent
amyloidosis
anaphylaxis
appendix perforation
arthralgia
arthritis
case report
child
clinical feature
consciousness disorder
diarrhea
drug efficacy
drug substitution
drug withdrawal
electrolyte disturbance
face edema
familial Mediterranean fever
female
fever
follow up
gastrointestinal biopsy
gastrointestinal symptom
heart amyloidosis
hemodialysis
hepatitis C
hospitalization
human
human tissue
hypoalbuminemia
hypotension
infection
joint swelling
kidney amyloidosis
kidney biopsy
kidney dysfunction
kidney transplantation
leg edema
long term care
male
malnutrition
medical literature
nephrotic syndrome
nutritional intolerance
pallor
priority journal
proteinuria
quality of life
remission
review
school
school child
supplementation
thorax pain
total parenteral nutrition
treatment outcome
vomiting
work resumption
Adolescent
Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Child
Colchicine
Drug Therapy, Combination
Familial Mediterranean Fever
Female
Follow-Up Studies
Gout Suppressants
Humans
Male
Treatment Outcome
Abstract: Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent selflimited attacks of fever and polyserositis. Reactive amyloid A amyloidosis is the most devastating complication of FMF, and amyloidosis continues to occur in the colchicine era in untreated and noncompliant patients. Unfortunately, there is no proven effective treatment for established amyloidosis. In this report, we present four FMF-related amyloidosis patients that were treated with long term infliximab therapy with the longest duration of follow-up, together with the literature review. Infliximab was very effective in controlling gastrointestinal system findings and protracted arthritis, and it also had a favorable impact on the clinical findings of nephrotic syndrome in these patients. In conclusion, by controlling debilitating complaints of amyloidosis with infliximab, quality of life increases in these patients, and they get rid of recurrent hospitalizations and return to school or work. © Clinical Rheumatology 2012.
URI: https://hdl.handle.net/11499/8528
https://doi.org/10.1007/s10067-012-2009-1
ISSN: 0770-3198
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

31
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

28
checked on Nov 21, 2024

Page view(s)

42
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.